Abstract
Three-dimensional (3D) cell culture techniques are frequently used to model alterations in tissue architecture critically important for tumor development. Here, we report on a detailed comparison of a spheroid model of human epidermal growth factor receptor (HER2) overexpressing cancer cells with the traditional monolayer culture. In 2D culture, HER2 and HER3 form heterodimers, whereas in multicellular spheroids HER2 homodimers are formed. These homodimers localize in membrane rafts, resulting in enhanced inhibition of the proliferation of cancer cells with trastuzumab (Herceptin), a monoclonal antibody specifically targeting HER2. Within the tumor spheroids, HER2 homodimerization leads to enhanced activation of HER2 and results in a switch in signaling pathways from phosphoinositide 3-kinase (PI3K) to mitogen-activated protein kinase (MAPK). Diminished PI3K signaling is accompanied by the activation of the integrin β4/Rac1/PAK 2 signaling cascade. We propose that the described 3D culture system may better reflect some in vivo aspects of HER signaling and can be used to further improve the understanding of the molecular mechanisms of trastuzumab action. Furthermore, the described human multicellular tumor spheroids may allow identification of new targets for the treatment of HER2-positive breast cancer patients who currently benefit suboptimally from trastuzumab treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P et al. (1998). Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 273: 20448–20455.
Guo H, Wei B, Zhang HY, Liu GJ, Bu H, Lang ZQ et al. (2005). [HER2 expression and its prognostic implication in lymph node negative breast carcinoma: a meta-analysis]. Zhonghua Bing Li Xue Za Zhi 34: 140–146.
Hudis CA . (2007). Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357: 39–51.
Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A . (1989). p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165–1172.
Jung J-H, Traugh JA . (2005). Regulation of the interaction of Pak2 with Cdc42 via autophosphorylation of serine 141. J Biol Chem 280: 40025–40031.
Kwon T, Kwon DY, Chun J, Kim JH, Kang SS . (2000). Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J Biol Chem 275: 423–428.
Lee GY, Kenny PA, Lee EH, Bissell MJ . (2007). Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4: 359–365.
Longva KE, Pedersen NM, Haslekås C, Stang E, Madshus IH . (2005). Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 116: 359–367.
Miljan EA, Bremer EG . (2002). Regulation of growth factor receptors by gangliosides. Sci STKE 2002: RE15.
Mocanu M-M, Fazekas Z, Petrás M, Nagy P, Sebestyén Z, Isola J et al. (2005). Associations of ErbB2, β1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett 227: 201–212.
Nagy P, Vereb G, Sebestyén Z, Horváth G, Lockett SJ, Damjanovich S et al. (2002). Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci 115: 4251–4262.
Nahta R, Esteva FJ . (2006). Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123–138.
Owens MA, Horten BC, Da Silva MM . (2004). HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5: 63–69.
Petersen OW, Rønnov-Jessen L, Howlett AR, Bissell MJ . (1992). Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 89: 9064–9068.
Pike LJ . (2006). Rafts defined: a report on the Keystone symposium on lipid rafts and cell function. J Lipid Res 47: 1597–1598.
Razani B, Schlegel A, Liu J, Lisanti MP . (2001). Caveolin-1, a putative tumour suppressor gene. Biochem Soc Trans 29: 494–499.
Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA et al. (2007). Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909–4919.
Schoenwaelder SM, Burridge K . (1999). Bidirectional signaling between the cytoskeleton and integrins. Curr Opin Cell Biol 11: 274–286.
Shaw KRM, Wrobel CN, Brugge JS . (2004). Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia 9: 297–310.
Shin S-I, Freedman VH, Risser R, Pollack R . (1975). Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA 72: 4435–4439.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712.
Sottocornola E, Berra B, Colombo I . (2003). GM3 content modulates the EGF-activated p185c-neu levels, but not those of the constitutively activated oncoprotein p185neu. Biochim Biophys Acta 1635: 55–66.
Sottocornola E, Misasi R, Mattei V, Ciarlo L, Gradini R, Garofalo T et al. (2006). Role of gangliosides in the association of ErbB2 with lipid rafts in mammary epithelial HC11 cells. FEBS J 273: 1821–1830.
Timms JF, White SL, O’Hare MJ, Waterfield MD . (2002). Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene 21: 6573–6586.
Wang SC, Hung MC . (2001). HER2 overexpression and cancer targeting. Semin Oncol 28: 115–124.
Weaver VM, Lelièvre S, Lakins JN, Chrenek MA, Jones JCR, Giancotti F et al. (2002). β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2: 205–216.
Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118–145.
Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL . (2002). Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132–4141.
Yamada KM, Cukierman E . (2007). Modeling tissue morphogenesis and cancer in 3D. Cell 130: 601–610.
Yarden Y . (2001). The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 (Suppl 4): S3–S8.
Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK et al. (2004). HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291: 1972–1977.
Zhou X, Tan M, Hawthorne VS, Klos KS, Lan KH, Yang Y et al. (2004). Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779–6788.
Acknowledgements
We thank Leopoldo Luistro for providing the SKOV-3 cell line. KPL-4 cells were kindly provided by Professor J Kurebayashi, Kawasaki Medical School, Kurashiki, Okayama, Japan. We are grateful to Olaf Mundigl and Heike Seul for their assistance with confocal microscopy, and Ute Baer for technical assistance with gene expression profiling. We gratefully acknowledge Manfred Kubbies for fruitful discussions and expert advice, Max Hasmann and Mark Sliwkowski for helpful discussions, Stefan Ries for critical review of the paper and Lynda Chang for medical writing support.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Pickl, M., Ries, C. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 28, 461–468 (2009). https://doi.org/10.1038/onc.2008.394
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.394
Keywords
This article is cited by
-
Carboxylated graphene quantum dots-mediated photothermal therapy enhances drug-membrane permeability, ROS production, and the immune system recruitment on 3D glioblastoma models
Cancer Nanotechnology (2023)
-
Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer
npj Breast Cancer (2023)
-
Evaluation of X-ray and carbon-ion beam irradiation with chemotherapy for the treatment of cervical adenocarcinoma cells in 2D and 3D cultures
Cancer Cell International (2022)
-
Engineering and Characterization of a Biomimetic Microchip for Differentiating Mouse Adipocytes in a 3D Microenvironment
Pharmaceutical Research (2022)
-
Polysaccharide hydrogel based 3D printed tumor models for chemotherapeutic drug screening
Scientific Reports (2021)